Premium
Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD. Authors' reply
Author(s) -
Rundquist Sara,
Sachs Michael C,
Eriksson Carl,
Olén Ola,
Montgomery Scott,
Halfvarson Jonas
Publication year - 2021
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16352
Subject(s) - vedolizumab , medicine , primary (astronomy) , inflammatory bowel disease , disease , physics , astronomy